Novogen oncology spin-out MEI acquires pracinostat as S*BIO divests more assets
This article was originally published in Scrip
Executive Summary
The publicly-traded Novogen oncology spin-out MEI Pharma has acquired pracinostat (SB939), an oral histone deacetylase (HDAC) inhibitor, for just $500,000 in MEI stock upfront, from Singapore-based S*BIO, as the private company's investors divest the last of its cancer drug assets.